Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A04076 | Pages: 272 | Charts: 70 | Tables: 129 |
The global cell-based assay market size was valued $11,744 million in 2020 and expected to reach $26,348 million by 2030, with a CAGR of 8.2% from 2021 to 2030. Cell-based assays are viable experimental instruments in life sciences and bio manufacturing. The principle of cell-based assay is based on cell culture procedures, in which living cells are produced in in-vitro and used as model systems for evaluating the biochemistry and physiology of both, healthy and sick cells.
Get more information on this report : Request Sample Pages
The cell-based assays are used to show a cell's viability, proliferation, cytotoxicity, senescence, and death rate. These assays rely on reporter gene assays, which have a high sensitivity due to signal amplification of cell-signaling cascades and are hence suited for cell-signaling cascade analysis. Cell-based assays are commonly used in high-throughput screening (HTS) formats. Various public and corporate entities have increased their R&D funding to discover better and safer pharmaceuticals. Furthermore, advances in cell-based assay technology have allowed researchers to use this method for drug discovery and toxicology studies. The growth of cell-based assay market is driven by factors, such as rise in demand for cell-based assays in drug discovery, higher financing for cell-based research, and increase in the number of drug discovery companies.
Because of the rise in cell-based applications in drug discovery and technological advancements in cell-based assay techniques, the demand for cell-based assays has expanded dramatically in recent years. Another important factor that drives market expansion is the increase in prevalence of lifestyle disorders, such as arthritis, diabetes, epilepsy, cancer, cardiovascular diseases, and others, which still have significant unmet needs and have prompted continued R&D investments. This market is also being driven by an increase in the usage of cell-based assay techniques for high throughput screening methods, such as toxicity studies, drug screening, in-vitro testing, and others. In addition, the market is being fueled by the adoption of high-throughput screening methodologies and an increase in R&D spending. However, the exorbitant costs of these tests, as well as a scarcity of competent professionals, are impeding their expansion. Furthermore, the growing popularity of label-free cell-based assays, as well as untapped potential in developing nations, present considerable prospects for market participants.
The World Health Organization (WHO) on January 30, 2020 declared COVID-19 as a pandemic and general wellbeing crisis of international concern. COVID-19 has impacted around 210 countries across the globe. Because of the COVID-19 pandemic, state-run administrations across the globe declared inescapable lockdowns as well as friendly distancing measures to forestall breakdown of the healthcare structure. States have additionally given constraints and preventions on undertakings and elective surgeries. These obstructions continue to influence the growth of different industries, and the enhanced response towards these regulations effect the industry. The scattering, production, and store network have been impacted, because of the execution of lockdown across the globe.
Similarly, the cell-based assay market was also impacted during the pandemic. According to the WHO, COVID-19 has been confirmed in 96,012,792 people, with 2,075,870 deaths (as of January 22, 2021). Companies have increased their R&D efforts to produce a vaccine and medications to combat the SARS-CoV-2 virus as a result of the pandemic. Vaccine-related research in pharmaceutical and biotechnological firms, research centers, and academic research institutes is regarded critical, and operations and output have been largely unaffected. Both, the availability of research funding and the demand for and manufacturing of cell-based test products are predicted to expand as a result of the increase in research activities. The industry's participants are modifying their long- and short-term growth strategies to capitalize on opportunities in the research market by introducing innovative goods to combat the pandemic. For both, researchers and laboratories, the rise in need for COVID-19 research has provided a wide scope for cell-based 45 tests in viral infection research, vaccine development, and overall drug discovery.
A variety of COVID-19 vaccines or antiviral medications have been approved or are in development, and patients are now being treated symptomatically. The functional efficiency of the antibodies produced to neutralize the target virus is assessed for both, vaccinations and treatments. To reduce the time and boost the throughput of these experiments, cell-based assays are used. As a result, the demand for cell-based assays to provide an early indication of the symptoms in patients has increased. Thus, the final impact of COVID-19 on cell-based assay markets is positive.
The cell-based assay market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is fragmented into consumable, instrument, service, and software. The consumable segment includes reagents, microplates, probes & labels, assay kits, cell lines, and others. Assay kits are further sub-divided into reporter gene assays, cell growth assays, second messenger assays, cell death assays, and others. Likewise, the cell lines are divided into immortalized cell lines, primary cell lines, and stem cell lines. On the basis of application, the cell-based assay market is classified into drug discovery, basic research, absorption, distribution, metabolism, & excretion (ADME) studies, predictive toxicology, and others. On the basis of end user, it is categorized into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. By region, it is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.
[PRODUCTTYPEGRAPH]
By product and service type, the cell-based assay market is segmented into consumables, instruments & software, and services. Consumables dominated the market in 2019 due to largest share, which is attributed to the extensive use and repeated purchase of consumables by pharmaceutical and biopharmaceutical companies and the rise in number of preliminary studies for the development of therapeutics.
[APPLICATIONTYPEGRAPH]
By application type, the cell-based assay market is categorized into drug discovery, basic research, and other applications. The drug discovery application segment dominated the market in 2020 due to the largest share which can be attributed to increasing R&D investments, technological innovations in supportive processes, the introduction of new drugs, and the growing number of CROs providing drug discovery services.
[ENDUSERTYPEGRAPH]
By end users, the cell-based assay market is segmented into pharmaceutical & biotechnology companies, academic & government research institutes, contract research organizations, and others. Pharmaceutical & biotechnology companies dominated the market in 2019 due to the largest share that is attributed to the increase in R&D expenditure, rise in number of drug discovery projects, and the adoption of strategic approaches such as collaborations to develop drug candidates.
[REGIONTYPEGRAPH]
By region type, in 2019 North America accounted for the largest share of the cell-based assays market, followed by Europe. The large share of the North American regional segment can be attributed to the availability of government and private funding for life science research, the growing penetration of CROs, comprehensive drug development regulations, and the rapid adoption of advanced technologies in the region.
Major key players operating in the global cell-based assay market are Becton, Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., General Electric Company, Merck KGaA, Perkinelmer, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., Cell Signaling Technology, Inc., and Promega Corporation. The other prominent players in the value chain include Macrogen, Inc., New England Biolabs, Inc., Cisbio Bioassays, Cell Biolabs, Inc., and DiscoverX Corporation
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profile in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porters five forces analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Rise in applications of cell-based assays
3.4.1.2.Surge in prevalence of infectious diseases and cancer worldwide
3.4.1.3.Rise in awareness regarding benefits of cell-based assays over traditional method
3.4.2.Restraint
3.4.2.1.Hight cost of cell-based assay products and services
3.4.3.Opportunity
3.4.3.1.Increase in R&D investments in drug discovery and development
3.4.3.2.Impact analysis
3.5.COVID-19 impact analysis for Cell-based assay market
CHAPTER 4:CELL-BASED ASSAY, BY PRODUCT & SERVICE
4.1.Overview
4.1.1.Market size and forecast
4.2.Consumables
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.2.4.Market size and forecast, by type
4.2.4.1.Reagents
4.2.4.1.1.Market size and forecast
4.2.4.2.Microplates
4.2.4.2.1.Market size and forecast
4.2.4.3.Probes & Labels
4.2.4.3.1.Market size and forecast
4.2.4.4.Assay Kits
4.2.4.4.1.Market size and forecast
4.2.4.4.2.Market size and forecast, by type
4.2.4.5.Reporter Gene Assays
4.2.4.5.1.Market size and forecast
4.2.4.6.Cell Growth Assays
4.2.4.6.1.Market size and forecast
4.2.4.7.Second Messenger Assays
4.2.4.7.1.Market size and forecast
4.2.4.8.Cell Death Assays
4.2.4.8.1.Market size and forecast
4.2.4.9.Other Assays
4.2.4.9.1.Market size and forecast
4.2.4.10.Cell Lines
4.2.4.10.1.Market size and forecast
4.2.4.10.2.Market size and forecast, by type
4.2.4.11.Immortalized Cell Line
4.2.4.11.1.Market size and forecast
4.2.4.12.Primary Cell Line
4.2.4.12.1.Market size and forecast
4.2.4.13.Stem Cell Lines
4.2.4.13.1.Market size and forecast
4.2.4.14.Other Cell Line
4.2.4.14.1.Market size and forecast
4.2.5.Other Consumables
4.2.5.1.Market size and forecast
4.3.Instruments
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Services
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Software
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:CELL-BASED ASSAY MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Drug Discovery
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.ADME Studies
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Basic Research
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Predictive Toxicology
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Other Applications
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:CELL-BASED ASSAY MARKET, BY END USER
6.1.Overview
6.1.1.Market size and forecast
6.2.Pharmaceutical and Biotechnology Companies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Academic and Government Research Institutes
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Contract Research Organizations
6.4.1.Market size and forecast, by region
6.4.2.=Market analysis, by country
6.5.Other
6.5.1.Market size and forecast, by region
6.5.2.Market analysis, by country
CHAPTER 7:CELL-BASED ASSAY MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.North America Cell-based assay market, by country
7.2.2.1.U.S.
7.2.2.1.1.Market size and forecast, by Product and Service
7.2.2.1.2.Market size and forecast, by application
7.2.2.1.3.Market size and forecast, by end user
7.2.2.2.Canada
7.2.2.2.1.Market size and forecast, by product and service
7.2.2.2.2.Market size and forecast, by application
7.2.2.2.3.Market size and forecast, by end user
7.2.2.3.Mexico
7.2.2.3.1.Market size and forecast, by product and service
7.2.2.3.2.Market size and forecast, by application
7.2.2.3.3.Market size and forecast, by end user
7.2.3.North America market size and forecast, by product and service
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by end user
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe Cell-based assay market, by country
7.3.2.1.Germany
7.3.2.1.1.Market size and forecast, by Product and service
7.3.2.1.2.Market size and forecast, by application
7.3.2.1.3.Market size and forecast, by end user
7.3.2.2.UK
7.3.2.2.1.Market size and forecast, by Product and service
7.3.2.2.2.Market size and forecast, by application
7.3.2.2.3.Market size and forecast, by end user
7.3.2.3.France
7.3.2.3.1.Market size and forecast, by Product and service
7.3.2.3.2.Market size and forecast, by application
7.3.2.3.3.Market size and forecast, by end user
7.3.2.4.Italy
7.3.2.4.1.Market size and forecast, by Product and service
7.3.2.4.2.Market size and forecast, by application
7.3.2.4.3.Market size and forecast, by end user
7.3.2.5.Spain
7.3.2.5.1.Market size and forecast, by Product and service
7.3.2.5.2.Market size and forecast, by application
7.3.2.5.3.Market size and forecast, by end user
7.3.2.6.Rest of Europe
7.3.2.6.1.Market size and forecast, by Product and service
7.3.2.6.2.Market size and forecast, by application
7.3.2.6.3.Market size and forecast, by end user
7.3.3.Europe market size and forecast, by Product and service
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by end user
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific Cell-based assay market, by country
7.4.2.1.China
7.4.2.1.1.Market size and forecast, by Product and service
7.4.2.1.2.Market size and forecast, by application
7.4.2.1.3.Market size and forecast, by end user
7.4.2.2.Japan
7.4.2.2.1.Market size and forecast, by Product and service
7.4.2.2.2.Market size and forecast, by application
7.4.2.2.3.Market size and forecast, by end user
7.4.2.3.Australia
7.4.2.3.1.Market size and forecast, by Product and service
7.4.2.3.2.Market size and forecast, by application
7.4.2.3.3.Market size and forecast, by end user
7.4.2.4.India
7.4.2.4.1.Market size and forecast, by Product and service
7.4.2.4.2.Market size and forecast, by application
7.4.2.4.3.Market size and forecast, by end user
7.4.2.5.South Korea
7.4.2.5.1.Market size and forecast, by Product application
7.4.2.5.2.Market size and forecast, by application
7.4.2.5.3.Market size and forecast, by end user
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Market size and forecast, by Product and service
7.4.2.6.2.Market size and forecast, by application
7.4.2.6.3.Market size and forecast, by end user
7.4.3.Asia-Pacific market size and forecast, by Product and service
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by end user
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA Cell-based assay market, by country
7.5.2.1.Brazil
7.5.2.1.1.Market size and forecast, by Product and service
7.5.2.1.2.Market size and forecast, by application
7.5.2.1.3.Market size and forecast, by end user
7.5.2.2.Saudi Arabia
7.5.2.2.1.Market size and forecast, by Product and service
7.5.2.2.2.Market size and forecast, by application
7.5.2.2.3.Market size and forecast, by end user
7.5.2.3.South Africa
7.5.2.3.1.Market size and forecast, by Product and service
7.5.2.3.2.Market size and forecast, by application
7.5.2.3.3.Market size and forecast, by end user
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Market size and forecast, by Product and service
7.5.2.4.2.Market size and forecast, by application
7.5.2.4.3.Market size and forecast, by end user
7.5.3.LAMEA market size and forecast, by Product and service
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by end user
CHAPTER 8:COMPETITION LANDSCAPE
8.1.Top winning strategies
8.2.Product mapping
8.3.Competitive dashboard
8.4.Competitive heatmap
8.5.Key developments
8.5.1.Acquisition
8.5.2.Product Launch
8.6.Top player positioning, 2021
CHAPTER 9:COMPANY PROFILES
9.1.BECTON, DICKINSON & COMPANY
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.BIO-RAD LABORATORIES, INC.
9.2.1.Company overview
9.2.2.Company Snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.CELL SIGNALING TECHNOLOGY, INC.
9.3.1.Company overview
9.3.2.Company Snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.4.DANAHER CORPORATION
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments
9.5.GENERAL ELECTRIC COMPANY
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance
9.5.6.Key strategic moves and developments
9.6.LONZA GROUP
9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio
9.6.5.Business performance
9.7.MERCK KGAA
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.8.PERKINELMER, INC.
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments
9.9.PROMEGA CORPORATION
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.10.THERMO FISCHER SCIENTIFIC, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020-2030 ($MILLION)
TABLE 02.CELL-BASED ASSAY MARKET FOR CONSUMABLES, BY REGION, 2020–2030 ($MILLION)
TABLE 03.CELL-BASED ASSAY MARKET FOR CONSUMABLES, BY TYPE, 2020–2030 ($MILLION)
TABLE 04.CELL-BASED ASSAY MARKET FOR ASSAY KITS, 2020–2030 ($MILLION)
TABLE 05.CELL-BASED ASSAY MARKET FOR CELL LINES, 2020–2030 ($MILLION)
TABLE 06.CELL-BASED ASSAY MARKET FOR INSTRUMENTS, BY REGION, 2020–2030 ($MILLION)
TABLE 07.CELL-BASED ASSAY MARKET FOR SERVICE, BY REGION, 2020–2030 ($MILLION)
TABLE 08.CELL-BASED ASSAY MARKET FOR SOFTWARE, BY REGION, 2020–2030 ($MILLION)
TABLE 09.CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 10.CELL-BASED ASSAY MARKET FOR DRUG DISCOVERY APPLICATION, BY REGION, 2020–2030 ($MILLION)
TABLE 11.CELL-BASED ASSAY MARKET FOR ADME STUDIES APPLICATION, BY REGION, 2020–2030 ($MILLION)
TABLE 12.CELL-BASED ASSAY MARKET FOR BASIC RESEARCH APPLICATION, BY REGION, 2020–2030 ($MILLION)
TABLE 13.CELL-BASED ASSAY MARKET FOR PREDICTIVE TOXICOLOGY, BY REGION, 2020–2030 ($MILLION)
TABLE 14.CELL-BASED ASSAY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 15.CELL-BASED ASSAY, BY END USER, 2020-2030 ($MILLION)
TABLE 16.CELL-BASED ASSAY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2030 ($MILLION)
TABLE 17.CELL-BASED ASSAY MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2020–2030 ($MILLION)
TABLE 18.CELL-BASED ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2030 ($MILLION)
TABLE 19.CELL-BASED ASSAY MARKET FOR OTHER, BY REGION, 2020–2030 ($MILLION)
TABLE 20.CELL-BASED ASSAY MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 21.NORTH AMERICA CELL-BASED ASSAY MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 22.U.S. CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 23.U.S. CELL-BASED ASSAY MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 24.U.S. CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 25.CANADA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 26.CANADA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 27.CANADA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 28.MEXICO CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 29.MEXICO CELL-BASED ASSAY MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 30.MEXICO CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 31.NORTH AMERICA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 32.NORTH AMERICA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 33.NORTH AMERICA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 34.EUROPE CELL-BASED ASSAY MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 35.GERMANY CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 36.GERMANY CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 37.GERMANY CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 38.UK CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 39.UK CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 40.UK CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 41.FRANCE CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 42.FRANCE CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 43.FRANCE CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 44.ITALY CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 45.ITALY CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 46.ITALY CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 47.SPAIN CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 48.SPAIN CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 49.SPAIN CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 50.REST OF EUROPE CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 52.REST OF EUROPE CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 53.EUROPE CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 54.EUROPE CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 55.EUROPE CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 56.ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 57.CHINA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 58.CHINA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 59.CHINA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 60.JAPAN CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 61.JAPAN CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 62.JAPAN CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 65.AUSTRALIA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 66.INDIA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 67.INDIA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 68.INDIA CELL-BASED ASSAY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 69.SOUTH KOREA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 71.SOUTH KOREA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 75.ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 76.ASIA-PACIFIC CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 77.ASIA-PACIFIC CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 78.LAMEA CELL-BASED ASSAY MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 79.BRAZIL CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 80.BRAZIL CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 81.BRAZIL CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 82.SAUDI ARABIA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 84.SAUDI ARABIA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 85.SOUTH AFRICA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 86.SOUTH AFRICA CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 87.SOUTH AFRICA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 88.REST OF LAMEA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 89.REST OF LAMEA CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 90.REST OF LAMEA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 91.LAMEA CELL-BASED ASSAY MARKET, BY PRODUCT AND SERVICE, 2020–2030 ($MILLION)
TABLE 92.CELL-BASED ASSAY, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 93.LAMEA CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 94.BD: COMPANY SNAPSHOT
TABLE 95.BD: OPERATING SEGMENTS
TABLE 96.BD: PRODUCT PORTFOLIO
TABLE 97.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.BIO-RAD: COMPANY SNAPSHOT
TABLE 99.BIO-RAD: OPERATING SEGMENTS
TABLE 100.BIO-RAD: PRODUCT PORTFOLIO
TABLE 101.BIO-RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.CST: COMPANY SNAPSHOT
TABLE 103.CST: OPERATING SEGMENTS
TABLE 104.CST: PRODUCT PORTFOLIO
TABLE 105.DANAHER: COMPANY SNAPSHOT
TABLE 106.DANAHER: OPERATING SEGMENTS
TABLE 107.DANAHER: PRODUCT PORTFOLIO
TABLE 108.DANAHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109.GE: COMPANY SNAPSHOT
TABLE 110.GE: OPERATING SEGMENTS
TABLE 111.GE: PRODUCT PORTFOLIO
TABLE 112.GE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.LONZA: COMPANY SNAPSHOT
TABLE 114.LONZA: OPERATING SEGMENTS
TABLE 115.LONZA: PRODUCT PORTFOLIO
TABLE 116.MERCK KGAA: COMPANY SNAPSHOT
TABLE 117.MERCK KGAA: OPERATING SEGMENTS
TABLE 118.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 119.PERKIN ELMER : COMPANY SNAPSHOT
TABLE 120.PERKIN ELMER : OPERATING SEGMENTS
TABLE 121.PERKIN ELMER: PRODUCT PORTFOLIO
TABLE 122.PERKIN ELMER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 123.PROMEGA: COMPANY SNAPSHOT
TABLE 124.PROMEGA: OPERATING SEGMENTS
TABLE 125.PROMEGA: PRODUCT PORTFOLIO
TABLE 126.THERMO FISHER: COMPANY SNAPSHOT
TABLE 127.THERMO FISHER: OPERATING SEGMENTS
TABLE 128.THERMO FISHER: PRODUCT PORTFOLIO
TABLE 129.THERMO FISHER: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 01.EXECUTIVE SUMMARY
FIGURE 02.CELL-BASED ASSAY MARKET SEGMENTATION
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.HIGH BARGANING POWER OF SUPPLIERS
FIGURE 05.MODERATE BARGANING POWER OF BUYERS
FIGURE 06.MODERATE THREAT OF SUBSTITUTION
FIGURE 07.MODERATE THREAT OF NEW ENTRANTS
FIGURE 08.HIGHLY COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.CELL-BASED ASSAY MARKET, BY PRODUCT & SERVICE, 2020–2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR CONSUMABLES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 12.REAGENT MARKET, 2020–2030 ($MILLION)
FIGURE 13.MICROPLATES MARKET, 2020–2030 ($MILLION)
FIGURE 14.PROBES AND LABELS MARKET, 2020–2030 ($MILLION)
FIGURE 15.ASSAY KITS MARKET, 2020–2030 ($MILLION)
FIGURE 16.REPORTER GENES MARKET, 2020–2030 ($MILLION)
FIGURE 17.CELL GROWTH ASSAYS MARKET, 2020–2030 ($MILLION)
FIGURE 18.SECOND MESSENGER ASSAYS MARKET, 2020–2030 ($MILLION)
FIGURE 19.CELL DEATH ASSAYS MARKET, 2020–2030 ($MILLION)
FIGURE 20.OTHER ASSAYS MARKET, 2020–2030 ($MILLION)
FIGURE 21.CELL LINES MARKET, 2020–2030 ($MILLION)
FIGURE 22.IMMORTALIZED CELL LINE MARKET, 2020–2030 ($MILLION)
FIGURE 23.PRIMARY CELL LINES MARKET, 2020–2030 ($MILLION)
FIGURE 24.STEM CELL LINE MARKET, 2020–2030 ($MILLION)
FIGURE 25.OTHER CELL LINES MARKET, 2020–2030 ($MILLION)
FIGURE 26.OTHER CONSUMABLES MARKET, 2020–2030 ($MILLION)
FIGURE 27.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR INSTRUMENTS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 28.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR SERVICE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 29.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR SOFTWARE, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 30.CELL-BASED ASSAY MARKET, BY APPLICATION, 2020–2030 (%)
FIGURE 31.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR DRUG DISCOVERY APPLICATION, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 32.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR ADME STUDIES APPLICATION, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 33.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR BASIC RESEARCH APPLICATION, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 34.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR PREDICTIVE TOXICOLOGY APPLICATION, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 35.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 36.CELL-BASED ASSAY MARKET, BY END USER, 2020–2030 (%)
FIGURE 37.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 38.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 39.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 40.COMPARATIVE ANALYSIS OF CELL-BASED ASSAY MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 41.CELL-BASED ASSAY MARKET, BY REGION, 2020–2030 (%)
FIGURE 42.TOP WINNING STRATEGIES, BY YEAR, 2020–2022
FIGURE 43.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022 (%)
FIGURE 44.TOP WINNING STRATEGIES, BY COMPANY, 2020–2022
FIGURE 45.PRODUCT MAPPING OF TOP 10 KEY PLAYERS
FIGURE 46.COMPETITIVE DASHBOARD OF TOP 10 KEY PLAYERS
FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 48.BD: REVENUE, 2019–2021 ($MILLION)
FIGURE 49.BD: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 50.BD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 51.BIO-RAD: REVENUE, 2019–2021 ($MILLION)
FIGURE 52.BIO-RAD: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 53.BIO-RAD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 54.DANAHER: REVENUE, 2019–2021 ($MILLION)
FIGURE 55.DANAHER: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 56.DANAHER: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 57.GE: REVENUE, 2019–2021 ($MILLION)
FIGURE 58.GE: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 59.GE: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 60.LONZA: REVENUE, 2019–2021 ($MILLION)
FIGURE 61.LONZA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 62.MERCK KGAA: REVENUE, 2019–2021 ($MILLION)
FIGURE 63.MERCK KGAA: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 64.MERCK KGAA: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 65.PERKIN ELMER: REVENUE, 2019–2021 ($MILLION)
FIGURE 66.PERKINELMER: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 67.PERKINELMER: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 68.THERMO FISHER: REVENUE, 2019–2021 ($MILLION)
FIGURE 69.THERMO FISHER: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 70.THERMO FISHER: REVENUE SHARE BY REGION, 2021 (%)